RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.

Regulatory Focus™ > News Articles > 2019 > 7 > Health Canada Consults on Revised Promotion Guidance

Health Canada Consults on Revised Promotion Guidance

Posted 08 July 2019 | By Michael Mezher 

Health Canada Consults on Revised Promotion Guidance

Health Canada on Thursday opened a two-month public consultation on a draft revision of its guidance on the difference between promotional and nonpromotional messages about health products such as drugs and medical devices.
The draft guidance is intended to replace the agency’s current policy on distinguishing between promotional and non-promotional activities, The Distinction Between Advertising and Other Activities, which was first issued in 1996 and updated in 2005.
Since then, Health Canada says the “advertising landscape has considerably evolved” and its policies need to be updated to account for how health products are promoted on the Internet and social media.
Health Canada says it developed the new draft guidance, The Distinction Between Promotional and Non-promotional Messages and Activities for Health Products, with input from two advertising preclearance agencies.
Non-governmental preclearance agencies, such as Advertising Standards Canada and the Pharmaceutical Advertising Advisory Board, are recognized by Health Canada to review promotional materials before they are disseminated to health care professionals or consumers.
“In consideration of today’s advertising context, practices and trends, Health Canada has been working with two advertising pre-clearance agencies to revise the policy into a more up to date, accurate and relevant draft guidance document,” Health Canada says.
Health Canada also says it hopes to receive comments from various stakeholders including academia, industry associations, health product manufacturers, advocacy groups and provincial/territorial authorities on the draft guidance. The consultation will be open for comments until 3 September 2019.
Health Canada


© 2022 Regulatory Affairs Professionals Society.